Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis.
Adolescent
Adult
Aged
Aged, 80 and over
COVID-19
/ complications
Cohort Studies
DNA, Bacterial
/ blood
Enterobacteriaceae
/ genetics
Female
Humans
Interferon Type I
/ blood
Lymphopenia
/ complications
Male
Micrococcaceae
/ genetics
Middle Aged
Nasopharynx
/ virology
Neoplasms
/ complications
Pandemics
Prognosis
RNA, Viral
/ analysis
SARS-CoV-2
/ genetics
Time Factors
Virus Shedding
Young Adult
Journal
Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
30
01
2021
accepted:
28
05
2021
revised:
26
05
2021
pubmed:
8
7
2021
medline:
15
12
2021
entrez:
7
7
2021
Statut:
ppublish
Résumé
Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during cancer therapies remain elusive. When comparing nasopharyngeal swabs from cancer and noncancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer), we found that malignant disease favors the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies. Cancer patients with a prolonged SARS-CoV-2 RNA detection exhibited the typical immunopathology of severe COVID-19 at the early phase of infection including circulation of immature neutrophils, depletion of nonconventional monocytes, and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, activated follicular T-helper cells, and non-naive Granzyme B
Identifiants
pubmed: 34230615
doi: 10.1038/s41418-021-00817-9
pii: 10.1038/s41418-021-00817-9
pmc: PMC8259103
doi:
Substances chimiques
DNA, Bacterial
0
Interferon Type I
0
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3297-3315Subventions
Organisme : European Research Council
Pays : International
Informations de copyright
© 2021. The Author(s).
Références
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
J Pathol. 2017 Dec;243(4):431-441
pubmed: 28892150
JAMA Intern Med. 2021 Jan 1;181(1):71-78
pubmed: 32910179
Nat Cancer. 2020 Aug;1(8):784-788
pubmed: 35122051
Nat Cancer. 2020 Oct;1(10):965-975
pubmed: 35121871
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Mol Cell. 2019 Oct 3;76(1):110-125.e9
pubmed: 31474573
Cancer Cell. 2020 Nov 9;38(5):661-671.e2
pubmed: 32997958
Cancer Commun (Lond). 2020 Aug;40(8):374-379
pubmed: 32666636
Cell Death Dis. 2021 Mar 11;12(3):258
pubmed: 33707411
Br J Haematol. 2020 Jul;190(1):e16-e20
pubmed: 32379921
Blood. 2007 May 1;109(9):3812-9
pubmed: 17255361
Travel Med Infect Dis. 2020 Jul - Aug;36:101632
pubmed: 32205269
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Clin Infect Dis. 2021 Nov 2;73(9):1745
pubmed: 34586376
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Eur J Cancer. 2020 Aug;135:251-259
pubmed: 32540204
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
Transfusion. 2016 May;56(5):1138-47
pubmed: 26865079
N Engl J Med. 2020 Dec 24;383(26):2586-2588
pubmed: 33259154
J Infect Dis. 2020 Sep 1;222(7):1103-1107
pubmed: 32702095
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
mBio. 2020 Sep 18;11(5):
pubmed: 32948688
Nature. 2020 May;581(7809):475-479
pubmed: 32461639
Elife. 2020 Dec 15;9:
pubmed: 33317695
Nat Cancer. 2020 Oct;1(10):946-964
pubmed: 35121872
Nat Metab. 2020 Mar;2(3):233-242
pubmed: 32694777
Nature. 2020 Jan;577(7790):410-415
pubmed: 31875848
JAMA Netw Open. 2020 Jul 1;3(7):e2016485
pubmed: 32697322
Crit Care. 2020 Sep 1;24(1):539
pubmed: 32873316
PLoS One. 2015 Nov 06;10(11):e0142334
pubmed: 26544955
Ann Oncol. 2020 Oct;31(10):1386-1396
pubmed: 32561401
Ann Intern Med. 2020 Sep 1;173(5):350-361
pubmed: 32422076
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
PLoS One. 2016 Feb 11;11(2):e0148258
pubmed: 26866481
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1011-1019
pubmed: 32291542
Travel Med Infect Dis. 2020 Jul - Aug;36:101791
pubmed: 32593867
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
J Oncol Pract. 2019 Apr;15(4):177-184
pubmed: 30970229
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
J Clin Microbiol. 2013 Jan;51(1):155-62
pubmed: 23100345
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
Ann Oncol. 2017 Aug 01;28(8):1988-1995
pubmed: 28595336
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Eur J Cancer. 2020 Nov;139:181-187
pubmed: 33035991
JCI Insight. 2018 Mar 8;3(5):
pubmed: 29515037
Cardiovasc Pathol. 2020 Sep - Oct;48:107233
pubmed: 32434133
Eur J Cancer. 2013 Mar;49(5):1080-9
pubmed: 23246297
Nature. 2020 Dec;588(7836):146-150
pubmed: 32726800
Cochrane Database Syst Rev. 2018 Feb 01;2:CD008983
pubmed: 29388675
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
J Clin Virol. 2020 Nov;132:104615
pubmed: 32927356
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
Gut. 2020 Jul;69(7):1362-1363
pubmed: 31203205
Nat Rev Immunol. 2020 Jun;20(6):351
pubmed: 32303696
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Nat Med. 2020 Aug;26(8):1218-1223
pubmed: 32581323
Gut. 2021 Apr;70(4):698-706
pubmed: 33431578
Zhonghua Bing Li Xue Za Zhi. 2020 Jun 8;49(6):576-582
pubmed: 32340089
Blood. 2010 Mar 11;115(10):2088-94
pubmed: 20042728
Bone Marrow Transplant. 2013 Nov;48(12):1548-53
pubmed: 23811816
Elife. 2014 Nov 11;3:
pubmed: 25385531
Bioinformatics. 2018 Apr 15;34(8):1287-1294
pubmed: 29228191
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
Lancet Haematol. 2020 Oct;7(10):e737-e745
pubmed: 32798473
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080